Valorum
New York, US · Founded 2021 · 14 employees on LinkedIn · 1 known investors
Valorum is a biosimilars company focused on commercializing biosimilar therapies with an emphasis on supply continuity, disciplined pricing, and buy-and-bill partnership models for physician practices, with an initial focus on oncology and ophthalmology. It serves clinicians and specialty care practices in the United States.
Also known as Valorum Biologics
Founders & leadership
Valorum was founded in 2021 by Par S. Hyare and Parvinder S. Hyare.
Investors · 1
Company profile
researched Aug 2026Valorum, which presents itself as Valorum Biologics, is a biosimilars company headquartered at 555 Madison Avenue, Suite 11D, New York, NY. It positions its commercial model around markets where clinicians retain decision-making authority over therapy selection, framing current biosimilar dynamics as unstable and commoditized for prescribing physicians.
The company describes three pillars of its offering: long-term commercialization strategies intended to support supply continuity and provider confidence; disciplined, predictable pricing meant to reduce price volatility for purchasers; and partnership structures designed around buy-and-bill purchasing and specialty care delivery in order to limit administrative and operational burden on practices. Valorum states it targets overlooked or underserved segments as well as foundational markets, and plans coverage across multiple therapeutic areas and practice settings, with an initial focus on oncology and ophthalmology. The site references an approach and portfolio section, and includes adverse event reporting instructions with a drug safety contact line and referral to FDA MedWatch.
Business model
Valorum commercializes biosimilar products to physician practices through partnership models built around buy-and-bill purchasing in specialty care settings, emphasizing supply continuity and predictable pricing rather than short-cycle price competition.
▸Full profile — market position, go-to-market, geography
Market position
Valorum frames itself against a biosimilar market it characterizes as volatile and commoditized, seeking to compete on supply dependability, pricing predictability and reduced operational burden for practices rather than on discounting alone.
Stated differentiators include long-term commercialization strategies for supply continuity, disciplined and predictable pricing, and commercial models designed for buy-and-bill and specialty care workflows, plus a focus on underserved biosimilar market segments.
Go-to-market
Direct engagement with physician practices and specialty care providers, supported by partnering inquiries via the company's contact channels; the company says it designed its model after consulting practices about their day-to-day operations.
Physicians, community specialty practices and specialty care providers in the United States, initially in oncology and ophthalmology, along with prospective commercial partners.
Geography
United States operations run from an office in New York, NY, with a US toll-free adverse event reporting line and reference to the FDA MedWatch program.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
▸Research sources · 1
primary sources listed
- Valorumvalorum.bio · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Valorum do?
- Valorum Biologics is a New York-based biosimilars company serving physician practices, initially in oncology and ophthalmology.
- Who founded Valorum?
- Valorum was founded by Par S. Hyare, Parvinder S. Hyare in 2021.
- Who are Valorum's investors?
- Valorum's investors include Evolution VC Partners.
- Where is Valorum headquartered?
- Valorum is headquartered in New York, US.